首页> Annals of oncology : official journal of the European Society for Medical Oncology> Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.

导出原文传递

翻译打印收藏纠错

第一作者： J,Remon

第一单位： Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

作者： J,Remon ^[1] ; C,Caramella ^[2] ; C,Jovelet ^[3] ; L,Lacroix ^[3] ; A,Lawson ^[4] ; S,Smalley ^[4] ; K,Howarth ^[4] ; D,Gale ^[5] ; E,Green ^[4] ; V,Plagnol ^[4] ; N,Rosenfeld ^[6] ; D,Planchard ^[1] ; M V,Bluthgen ^[1] ; A,Gazzah ^[1] ; C,Pannet ^[1] ; C,Nicotra ^[1] ; E,Auclin ^[1] ; J C,Soria ^[7] ; B,Besse ^[7]

作者单位： Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. ^[1] Radiology, Gustave Roussy, Université Paris-Saclay, Villejuif, France. ^[2] Translational Research Laboratory, AMMICA, INSERM US23/CNRS UNS3655, Gustave Roussy, Villejuif, France. ^[3] Inivata Ltd, Cambridge, UK. ^[4] Inivata Ltd, Cambridge, UK.;Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK. ^[5] Inivata Ltd, Cambridge, UK.;Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.;Cambridge Cancer Centre, Cambridge, UK. ^[6] Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.;University Paris-Sud and Gustave Roussy Cancer Campus, Villejuif, France. ^[7]

关键词 EGFR mutation T790M ctDNA liquid biopsies lung cancer osimertinib